Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.51 |
| ▸ | UBE2N | P61088 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171480 | 0.88 | MAPT (0.56) | MAPTTHRBUBE2NTP53RXFP1 | |
| SCHEMBL4171474 | 0.81 | TP53 (0.60) | MAPTTHRBUBE2NTP53RXFP1 | |
| SCHEMBL3236024 | 0.78 | MAPT (0.51) | MAPTUBE2NTP53P2RX3ADORA3 | |
| SCHEMBL4186155 | 0.77 | TP53 (0.58) | MAPTTHRBUBE2NTP53RXFP1 | |
| SCHEMBL3236028 | 0.77 | ALDH1A1 (0.46) | MAPTTHRBTP53RXFP1P2RX3 | |
| SCHEMBL4173503 | 0.76 | TP53 (0.51) | MAPTTHRBUBE2NTP53P2RX3 | |
| SCHEMBL4172007 | 0.75 | KDM4E (0.43) | MAPTTP53RXFP1ADORA3ALDH1A1 | |
| SCHEMBL4181523 | 0.74 | UBE2N (0.49) | MAPTTHRBUBE2NTP53RXFP1 | |
| SCHEMBL7651132 | 0.74 | MAPT (0.50) | MAPTTHRBUBE2NRXFP1ADORA3 | |
| SCHEMBL4168727 | 0.73 | UBE2N (0.48) | MAPTTHRBUBE2NTP53RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | claimed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | claimed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088439-A1 | Diazinane Compounds | GABRB1, GRPR, GIPR | MAPT 3675/4885THRB 619/4885UBE2N 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.